

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	12/29/2003
CONVEYING PARTY DATA	
Name	Execution Date
PPD Discovery, Inc.	12/29/2003
RECEIVING PARTY DATA	
Name:	Pharmaceutical Product Development, Inc.
Street Address:	3151 South 17th Street
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28412
PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	6191147
Patent Number:	6664277
Patent Number:	6649638
Patent Number:	7166619
Application Number:	12020475
Patent Number:	6960603
Patent Number:	7112596
Application Number:	11457788
Application Number:	11618932
CORRESPONDENCE DATA	
Fax Number:	(303)863-0223
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	nnoblitt@sheridanross.com
Correspondent Name:	Robert D. Traver

CH \$360.00 6191147

500771029

PATENT  
REEL: 022191 FRAME: 0690

Address Line 1:	1560 Broadway, Suite 1200
Address Line 4:	Denver, COLORADO 80202

ATTORNEY DOCKET NUMBER:	4220
-------------------------	------

NAME OF SUBMITTER:	Robert D. Traver
--------------------	------------------

Total Attachments: 3 source=Merger_Docs#page1.tif source=Merger_Docs#page2.tif source=Merger_Docs#page3.tif
--

**ARTICLES OF MERGER  
FOR MERGER OF  
PPD DISCOVERY, INC. WITH AND INTO PHARMACEUTICAL PRODUCT  
DEVELOPMENT, INC.**

Pursuant to § 55-11-05 of the North Carolina General Statutes, PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. (the "Surviving Corporation"), a North Carolina corporation, hereby submits these Articles of Merger for the purpose of merging its subsidiary, PPD DISCOVERY, INC., a North Carolina corporation (the "Merging Corporation"), with and into the Surviving Corporation:

1. The Agreement and Plan of Merger attached hereto as Exhibit A was duly approved by the board of directors of the Surviving Corporation in the manner prescribed by Chapter 55 of the North Carolina General Statutes.

2. Shareholder approval of the Agreement and Plan of Merger was not required because the Surviving Corporation was the owner of at least ninety percent (90%) of the issued and outstanding shares of each class of the Merging Corporation, and the Agreement and Plan of Merger does not provide for any changes in the Articles of Incorporation of the Surviving Corporation that require shareholder approval.


3. These Articles of Merger shall be effective upon filing.

This the 29<sup>th</sup> day of December, 2003.

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

By: 

Its: President



**AGREEMENT AND PLAN OF MERGER  
TO MERGE  
PPD DISCOVERY, INC. WITH AND INTO PHARMACEUTICAL PRODUCT  
DEVELOPMENT, INC.**

THIS AGREEMENT AND PLAN OF MERGER ("Agreement") is made this 29<sup>th</sup> day of December, 2003, by and between PPD DISCOVERY, INC., a North Carolina corporation (the "Merging Corporation") and PHARMACEUTICAL PRODUCT DEVELOPMENT, INC., a North Carolina corporation (the "Surviving Corporation").

**RECITALS**

A. Merging Corporation is authorized to issue 100,000 shares of capital stock, of which 10 shares are issued and outstanding. The Surviving Corporation is the sole shareholder of the Merging Corporation, owning all 10 shares which are issued and outstanding.

B. The Surviving Corporation wishes to merge the Merging Corporation with and into the Surviving Corporation. Upon the merger, all shares of the Merging Corporation will be surrendered and canceled and the Surviving Corporation will remain and continue in existence.

**AGREEMENT**

For good and valuable consideration, the receipt and sufficiency of which the parties acknowledge, the parties agree as follows:

1. **Merger.** The merger of the Merging Corporation into the Surviving Corporation will be effected pursuant to the terms and conditions of this Agreement. Upon the merger becoming effective, the corporate existence of the Merging Corporation will cease, and the corporate existence of the Surviving Corporation will continue.

2. **Effective Time of Merger.** The merger shall be effective upon the filing of the Articles of Merger with the North Carolina Secretary of State (the "Effective Time").

3. **Conversion and Exchange of Shares of Merging Corporation.** At the Effective Time, the outstanding shares of the corporations participating in the merger will be converted and exchanged as follows:

(a) **Surviving Corporation.** The outstanding shares of the Surviving Corporation will not be converted, exchanged or altered in any manner as a result of the merger and will remain outstanding as shares of the Surviving Corporation.


(b) **Merger Corporation.** All authorized and outstanding shares of common stock of the Merging Corporation, all of which shares are owned by the Surviving Corporation, and all rights in respect thereof, will be canceled and the certificates representing such shares will be surrendered and canceled in exchange for \$1.00 per share.

4. **Abandonment.** After approval of this Agreement by the board of directors of the Surviving Corporation, and at any time prior to the Effective Time, the board of directors of the Surviving Corporation may, in its discretion, abandon the merger.

IN WITNESS WHEREOF, the parties have executed this Agreement and Plan of Merger through their duly authorized representatives to be effective as of the 29<sup>th</sup> day of December, 2003.


PPD DISCOVERY, INC.

By:

  
V. C. A. President

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

By:

  
President